Sigma to Acquire BioReliance - Analyst Blog
January 11 2012 - 3:30AM
Zacks
Life science and technology
company, Sigma-Aldrich Corporation (SIAL)
announced that it has agreed to buy BioReliance Holdings Inc., from
private equity firm Avista Capital Partners for $350 million in
cash. The acquisition is expected to close in the first quarter of
2012.
BioReliance Holdings provides
biopharmaceutical testing services to pharmaceutical,
biopharmaceutical, diagnostics, and other life science customers.
BioReliance generated revenues of approximately $110 million in
2010 was projected to have double-digit growth expected in 2011.
Avista Capital Partners acquired BioReliance in 2007.
The addition of BioReliance's
industry-leading QA/QC testing services to Sigma’s product
portfolio will enable Sigma to build better and more customized
products. The acquisition will extend Sigma’s reach into the
promising new market of biologic drugs. Sigma-Aldrich expects
the acquisition to be modestly accretive to its earnings per share
in 2012. Sigma- Aldrich expects to fund the acquisition with a
combination of existing cash and credit facilities.
As per BioReliance, the acquisition
creates one of the broadest product and service offerings for the
development and manufacture of biological drugs.
In Late October 2011, Sigma-Aldrich
delivered third-quarter earnings of 96 cents per share, surpassing
the Zacks Consensus Estimate of 91 cents per share and an increase
of 16% year over year.
The company incurred restructuring
costs of 1 cent per share, including which earnings came in at 95
cents per share versus the prior-year earnings of 76 cents per
share.
Reported sales in the third quarter
of 2011 were $626 million, increasing 11% year over year, but
missing the Zacks Consensus Estimate of $631 million. Excluding 5%
impact from currency exchange rates and 2% from acquisitions,
third-quarter organic sales growth came in at 4%.
For full-year 2011, the company
reiterated its expectation of organic sales to grow in the
mid-single digit range. At current exchange rates, currency is
expected to increase reportable sales for full year by
approximately 4%. Acquisitions are expected to increase sales by
another 1-2%.
The company revised its diluted
adjusted EPS forecast for 2011 (excluding restructuring charges) in
the range of $3.73 to $3.81 to reflect strong operating results
through the first nine months and a lower effective tax rate. This
represents an increase of 13% to 15% compared to 2010's adjusted
diluted EPS of $3.31. The company expects its fourth-quarter
diluted adjusted EPS to be in the range of $0.85 to $0.93.
St. Louis, Missouri-based
Sigma-Aldrich Corporation is a leading life sciences and high
technology company. It develops, manufactures and distributes
various biochemicals and organic chemicals.
Apart from acquisitions, in order
to boost its growth, Sigma-Aldrich plans to increase its focus on
marketing, business development, R&D while continuing with its
efforts to improve process and operations management.
Sigma-Aldrich faces stiff
competition from Bayer AG (BAYRY) and privately
held companies Brenntag AG and VWR International, LLC. We currently
maintain a Zacks #3 Rank (short-term Hold recommendation) on Sigma
and a long-term Neutral recommendation.
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
SIGMA ALDRICH (SIAL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(MM) (NASDAQ:SIAL)
Historical Stock Chart
From May 2024 to Jun 2024
(MM) (NASDAQ:SIAL)
Historical Stock Chart
From Jun 2023 to Jun 2024